Despite the proven benefits of liposomal encapsulation of drugs, 25 years of research has not solved the primary problem: intracellular delivery of liposome-encapsulated drug to target cells is inefficient. With currently applied liposome technologies, intracellular delivery is based upon non-specific leakage of the encapsulated drug out of the liposomes and across cell membranes. It has been well demonstrated that this delivery pathway leads to a systemic distribution of the drug and uptake by the reticulo-endothelial system, resulting in significant off-target toxicities. Furthermore, the delivery system itself is restricted to drugs that possess inherent membrane penetration capabilities.
The Fusogenix system incorporates Innovascreen's proprietary fusion-associated small transmembrane (FAST) proteins. These FAST proteins mediate efficient liposome-cell fusion, bypassing the degradative endocytic entry pathway, releasing their contents directly into the cytoplasm. FAST-liposomes fuse to a broad range of cell types and have no inherent receptor-binding activity, making them compatible with emerging antibody- or peptide-based targeting technology.
FAST-liposomes cause the lipids of opposing cell membranes to mix until the cells are completely fused. Incorporation of FAST protein into Innovascreen`s Fusogenix liposomes increases the frequency of membrane fusion more than 80x compared to conventional liposomes.Download Fusogenix Platform Factsheet